CRI Center for Chemical Proteomics, Department of Chemistry, Seoul National University, Seoul, 08826, Korea.
Department of Biophysics and Chemical Biology, Seoul National University, Seoul, 08826, Korea.
Angew Chem Int Ed Engl. 2021 Jan 25;60(4):1831-1838. doi: 10.1002/anie.202013915. Epub 2020 Dec 23.
Tau protein aggregates are a recognized neuropathological feature in Alzheimer's disease as well as many other neurodegenerative disorders, known as tauopathies. The development of tau-targeting therapies is therefore extremely important but efficient strategies or protein targets are still unclear. Here, we performed a cell-based phenotypic screening under endoplasmic reticulum (ER) stress conditions and identified a small molecule, SB1617, capable of suppressing abnormal tau protein aggregation. By applying label-free target identification technology, we revealed that the transient enhancement of protein kinase-like endoplasmic reticulum kinase (PERK) signaling pathway through the inhibition of stress-responsive SB1617 targets, PDIA3 and DNAJC3, is an effective strategy for regulating proteostasis in tauopathies. The molecular mechanism and the promising efficacy of SB1617 were demonstrated in neuronal cells and a mouse model with traumatic brain injury, a tauopathy known to involve ER stress.
tau 蛋白聚集体是阿尔茨海默病以及许多其他神经退行性疾病(称为 tau 病)的公认神经病理学特征。因此,tau 靶向治疗的发展极其重要,但有效的策略或蛋白靶点仍不清楚。在这里,我们在内质网 (ER) 应激条件下进行了基于细胞的表型筛选,并鉴定出一种能够抑制异常 tau 蛋白聚集的小分子 SB1617。通过应用无标记靶标鉴定技术,我们揭示了通过抑制应激反应性 SB1617 靶标 PDIA3 和 DNAJC3 来短暂增强蛋白激酶样内质网激酶 (PERK) 信号通路是调节 tau 病中蛋白质稳定性的有效策略。在神经元细胞和外伤性脑损伤(已知涉及内质网应激的 tau 病)的小鼠模型中,证明了 SB1617 的分子机制和有希望的疗效。